Bridges Thomas M, Lindsley Craig W
Vanderbilt Program in Drug Discovery, Department of Pharmacology, Vanderbilt Medical Center, Nashville, Tennessee 37232, USA.
ACS Chem Biol. 2008 Sep 19;3(9):530-41. doi: 10.1021/cb800116f. Epub 2008 Jul 25.
Heterotrimeric G-protein-coupled receptors (GPCRs) represent a large protein family responsible for mediating extracellular to intracellular signaling within a broad range of physiological contexts. Various conventional models have been used to describe their interactions with ligands and G-proteins. In recent years, however, numerous novel ligand-receptor interactions not adequately addressed by classical receptor theory have been recognized. In addition to traditional orthosteric ligands, many GPCRs can bind allosteric ligands that modulate receptor activity by interacting with distinct or overlapping receptor sites. Such ligands include positive allosteric modulators, which have become the focus of pharmaceutical drug discovery programs and have gained the attention of a growing body of basic and translational researchers within the academic community. Here, we review the fundamental aspects of allosteric GPCR modulation by small-molecule ligands, with particular focus on the emerging position of positive allosteric modulators in modern drug discovery.
异源三聚体G蛋白偶联受体(GPCRs)是一个庞大的蛋白质家族,负责在广泛的生理环境中介导细胞外到细胞内的信号传导。各种传统模型已被用于描述它们与配体和G蛋白的相互作用。然而,近年来,人们已经认识到许多经典受体理论未能充分解决的新型配体-受体相互作用。除了传统的正构配体,许多GPCRs还可以结合变构配体,这些变构配体通过与不同或重叠的受体位点相互作用来调节受体活性。这类配体包括正变构调节剂,它们已成为药物研发项目的重点,并引起了学术界越来越多基础和转化研究人员的关注。在这里,我们综述了小分子配体对GPCR变构调节的基本方面,特别关注正变构调节剂在现代药物研发中的新兴地位。